Document is current
Any future updates will be listed below
-
Authors
Zerbib, Johanna
Ippolito, Marica Rosaria https://orcid.org/0000-0001-7310-1871
Eliezer, Yonatan
De Feudis, Giuseppina
Reuveni, Eli
Savir Kadmon, Anouk
Martin, Sara
Viganò, Sonia https://orcid.org/0000-0003-0437-0087
Leor, Gil
Berstler, James
Muenzner, Julia https://orcid.org/0000-0002-5402-5890
Mülleder, Michael https://orcid.org/0000-0001-9792-3861
Campagnolo, Emma M.
Shulman, Eldad D. https://orcid.org/0000-0002-1859-8819
Chang, Tiangen https://orcid.org/0000-0003-1485-1992
Rubolino, Carmela
Laue, Kathrin
Cohen-Sharir, Yael
Scorzoni, Simone
Taglietti, Silvia
Ratti, Alice
Stossel, Chani
Golan, Talia
Nicassio, Francesco https://orcid.org/0000-0002-5954-5318
Ruppin, Eytan https://orcid.org/0000-0002-7862-3940
Ralser, Markus https://orcid.org/0000-0001-9535-7413
Vazquez, Francisca https://orcid.org/0000-0002-2857-4685
Ben-David, Uri https://orcid.org/0000-0001-7098-2378
Santaguida, Stefano https://orcid.org/0000-0002-1501-6190
- License Information
-
More Information
Article History
Received: 12 June 2024
Accepted: 28 August 2024
First Online: 9 September 2024
Competing interests
: U.B.-D. received grant funding from Novocure, and receives consulting fees from Accent Therapeutics. E.Ruppin is a co-founder of MedAware, Meabomed and Pangea Biomed (divested), and an unpaid member of Pangea Biomed’s scientific advisory board. F.V. receives research support from the Dependency Map Consortium, Riva Therapeutics, Bristol Myers Squibb, Merck, Illumina, and Deerfield Management. F.V. is on the scientific advisory board of GSK, is a consultant and holds equity in Riva Therapeutics and is a co-founder and holds equity in Jumble Therapeutics. The other authors declare no competing interests.
